| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1372181 | Bioorganic & Medicinal Chemistry Letters | 2011 | 4 Pages |
Abstract
We report the outcome of a high-throughput small-molecule screen to identify novel, nontoxic, inhibitors of Trypansoma cruzi, as potential starting points for therapeutics to treat for both the acute and chronic stages of Chagas disease. Two compounds were identified that displayed nanomolar inhibition of T. cruzi and an absence of activity against host cells at the highest tested dose. These compounds have been registered with NIH Molecular Libraries Program (probes ML157 and ML158).
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Andrew R. Germain, Leigh C. Carmody, Chris Dockendorff, Cristina Galan-Rodriguez, Ana Rodriguez, Stephen Johnston, Joshua A. Bittker, Lawrence MacPherson, Sivaraman Dandapani, Michelle Palmer, Stuart L. Schreiber, Benito Munoz,